Aortic stenosis
Review argues Lp(a) is an under-recognised, modifiable driver of aortic stenosis progression as targeted drugs emerge (Int J Cardiol Heart Vasc 2024)
Original title: Role of Lipoprotein (A) in aortic valve stenosis: Novel disease mechanisms and emerging pharmacotherapeutic approaches
This review examines the mechanistic role of Lp(a) in the pathogenesis and progression of aortic stenosis (AS), an area the authors argue remains overlooked in routine clinical assessment despite growing evidence of Lp(a)'s contribution. It surveys emerging pharmacotherapeutic approaches aimed at modulating Lp(a) levels to slow AS progression, and calls on cardiologists and physicians to proactively recognise and address elevated Lp(a) as a modifiable risk factor in AS management, similar to the imperative for active patient engagement seen elsewhere in cardiovascular care. The review positions closing this gap between mechanistic understanding and clinical practice as central to improving outcomes as novel Lp(a)-targeted therapies move toward clinical use in AS.
Original abstract
Lipoprotein(a) (Lp(a)) has garnered increasing attention as a significant contributor to the pathogenesis of aortic stenosis (AS), prompting a focused investigation into innovative pharmacological strategies to target this lipoprotein and its associated risks. Despite its recognized role in AS progression, Lp(a) often remains overlooked in clinical assessments, mirroring the broader challenges observed in holistic disease management. This review delves into the mechanistic intricacies of Lp(a) involvement in AS pathophysiology and its potential as a therapeutic target. Drawing parallels with the imperative for healthcare providers to proactively engage with patients regarding treatment regimens, this review underscores the essential role of cardiologists and physicians in recognizing and addressing Lp(a) as a modifiable risk factor in AS management. Furthermore, it explores promising avenues of novel drug approaches, including emerging pharmacotherapies and targeted interventions, aimed at modulating Lp(a) levels and attenuating AS progression. By navigating the complexities of Lp(a) modulation and its implications for AS management, this review aims to bridge critical gaps in understanding and clinical practice, ultimately optimizing treatment strategies and improving patient outcomes in the realm of AS therapeutics.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.